Rejected from Biomedicine & Pharmacotherapy? Where to Submit Next

Use these facts as routing checks, not as automatic resubmission reasons.

Verify the live ScienceDirect guide before quoting metrics, article-type language, submission-system steps, or declaration requirements in a cover letter.

This page was researched from current ScienceDirect journal, guide-for-authors, journal-insights, and review-proposal pages; Elsevier's Biomedicine & Pharmacotherapy conflict-of-interest policy; the NLM catalog record; existing Manusights Biomedicine & Pharmacotherapy sibling pages; and adjacent Manusights pages for pharmacology, oncology, drug delivery, cell death, phytomedicine, and biological-macromolecule routing.

The non-obvious layer is center-of-gravity diagnosis. A rejected Biomedicine & Pharmacotherapy manuscript may still be a Biomedicine & Pharmacotherapy paper if the rejection exposed a repairable bridge between pharmacology, disease relevance, and therapeutic consequence. It may be a JPET-style pharmacology paper if quantitative mechanism owns the contribution. It may be a Cancer Letters paper if oncology mechanism owns it, a Journal of Controlled Release or International Journal of Pharmaceutics paper if delivery/formulation owns it, a Cell Death & Disease paper if cell-death mechanism owns it, a Phytomedicine paper if the natural-product and ethnopharmacology story owns it, or a disease-specific translational journal paper if the audience is narrower than Biomedicine & Pharmacotherapy.

In our review work with Biomedicine & Pharmacotherapy-targeted manuscripts, the repeated pattern is a manuscript that uses pharmacotherapy language without proving the pharmacotherapy consequence. The title names therapy, the abstract names disease relevance, and the cover letter names the journal, but the first figure, methods, dose-response table, validation model, or clinical rationale does not carry that bridge.

Do not treat rejection as a reason to downgrade automatically. Sometimes the stronger move is lateral retargeting into the journal whose reviewers care about the actual evidence.

Use these labels to turn the decision letter into a repair plan.

Pharmacotherapy-bridge gap: the manuscript says "therapeutic," "pharmacological," or "clinical relevance," but the title, abstract, first figure, and cover letter do not show how the intervention, mechanism, disease model, and outcome connect.

Mechanism-consequence gap: the methods and results show a molecular, cellular, animal, or clinical effect, but the paper does not explain why that effect changes pharmacotherapy understanding.

Disease-lane gap: the manuscript is primarily oncology, cardiac, neurodegenerative, infectious-disease, inflammation, metabolism, or immunology work. The field is inside the journal's interests, but a specialist disease journal may own the audience more clearly.

Article-shape gap: the file reads like a review, preliminary communication, letter, or short disease-mechanism note while the package sells it as a full original research article. Retargeting without fixing article shape can reproduce the same rejection.

Declaration-package gap: the manuscript has a scientific argument, but competing interests, author metadata, ethics statements, data availability, figure files, review-proposal materials, or cover-letter fit are not clean enough for another submission cycle.

These labels prevent cosmetic retargeting. A pharmacotherapy-bridge gap is not fixed by adding "translational" to the abstract. A mechanism-consequence gap is not fixed by a broader disease introduction. A disease-lane gap is not fixed by submitting to a journal with a broader title.

The right next venue is the one where the paper's strongest evidence becomes central rather than defensive.

Rebuild for Biomedicine & Pharmacotherapy only if the manuscript still clears the journal's fit test: it belongs at the interface of clinical or basic medicine and pharmacology, and the evidence supports the therapeutic language.

Route back toward Biomedicine & Pharmacotherapy if:

• the editor invited a revised submission or transfer-back path
• the rejection reason was narrow and repairable
• the title, abstract, and first figure can show the pharmacotherapy bridge honestly
• mechanism, model choice, statistics, and translational consequence can be strengthened without changing the central claim
• the cover letter can explain why this journal is better than a disease-specific, drug-delivery, oncology, natural-product, or mechanistic pharmacology journal
• the review-proposal file is available and convincing if the manuscript is a review

Do not rebuild for Biomedicine & Pharmacotherapy if the real contribution is a disease-mechanism paper, a delivery-platform paper, a natural-product activity screen, a descriptive clinical association, a cell-death pathway paper, or a biomacromolecule materials paper that does not need a broad pharmacotherapy audience.

A mechanistic pharmacology route is cleaner when the rejection tells you the paper's strongest value is drug action rather than broad biomedical translation. That can include receptor activity, signaling pathway causality, dose-response logic, pharmacodynamics, pharmacokinetics, toxicology, quantitative exposure-response analysis, or a drug-mechanism comparison.

Use JPET-style routing when the paper's best reviewer is a pharmacologist asking whether the mechanism and quantitative evidence are convincing. Use Pharmacology & Therapeutics only if the manuscript is genuinely a review or synthesis, not an original research article trying to become a review after rejection.

This is not a downgrade. It is a way to place a pharmacology-centered manuscript in front of reviewers who will value the evidence instead of asking why the paper is not broader clinical-basic medicine.

Oncology routing is cleaner when the paper's first figure, mechanism, disease model, and discussion are all cancer-centered. Compare Cancer Letters when the manuscript is mechanism-driven cancer biology or experimental therapeutics.

Drug-delivery routing is cleaner when the carrier, formulation, release profile, PK/PD exposure, targeting system, or pharmaceutical technology is the actual innovation. Compare Journal of Controlled Release when the delivery platform is the story.

Cell-death routing is cleaner when apoptosis, necroptosis, ferroptosis, pyroptosis, autophagy-linked death, or pathway causality owns the manuscript. Compare Cell Death and Disease when the disease implication depends on cell-death biology.

Natural-product routing is cleaner when the evidence is built around plant-derived compounds, ethnopharmacology, phytochemistry, or natural-product intervention logic. Compare Phytomedicine when the natural-product identity is central rather than incidental.

In our review of Biomedicine & Pharmacotherapy-targeted manuscripts, the worst retargeting mistakes happen when authors treat every biomedical, pharmacology, oncology, and translational journal as interchangeable. The decision usually turns on which audience owns the evidence, not which journal title sounds closest to the rejected target.

Biomedicine & Pharmacotherapy interface pattern: the manuscript says it sits between basic medicine, clinical medicine, and pharmacology, but the abstract and first figure make only one side visible. A basic-mechanism paper with no therapeutic consequence should not be sold as pharmacotherapy. A clinical association paper with no drug mechanism should not be sold as pharmacology. The next journal should match the side that actually carries the evidence.

Biomedicine & Pharmacotherapy mechanism-consequence pattern: the methods and results show a molecular or cellular effect, but the discussion never turns that effect into pharmacotherapy meaning. We check whether the dose-response table, model choice, controls, statistical analysis, and limitations paragraph support the therapeutic language used in the title and conclusion. If they do not, a second broad pharmacotherapy submission will usually repeat the same problem.

Biomedicine & Pharmacotherapy disease-lane pattern: the paper may be strong, but the disease audience is more precise than the journal's broad scope. A cancer mechanism paper may need oncology reviewers. A cardiac model paper may need cardiovascular reviewers. A neurodegenerative disease paper may need neuroscience or neurology reviewers. An infectious-disease pharmacology paper may need antimicrobial or infectious-disease reviewers. In these cases, specialization can improve fit.

Biomedicine & Pharmacotherapy article-shape pattern: the file behaves like a review, preliminary communication, letter, or short disease-mechanism note while the package sells it as a full research article. For reviews, the ScienceDirect policy expects a separate Review Proposal file in Editorial Manager. For short claims, the abstract, first figure, and cover letter need to respect the actual article shape instead of inflating the manuscript into a full pharmacotherapy story.

An anonymized case pattern we would flag before retargeting: the abstract claimed a therapeutic advance in a cancer model, the first figure showed only expression changes and viability assays, the methods had no rescue or dose-response discipline, the cover letter argued broad pharmacotherapy relevance, and the limitations paragraph did not name the missing animal or patient-sample evidence. That package should not move unchanged. Either add the mechanism and validation that make the Biomedicine & Pharmacotherapy claim honest, or retarget the manuscript to a narrower oncology, molecular biology, or preliminary-communication route.

This is why the next move should start with the rejection reason, not with a list of journal metrics.

If you want a second read before choosing the next route, run a Biomedicine and Pharmacotherapy journal-fit and evidence-strength check. The useful question is not "which journal is easiest?" It is "which reviewers will value the actual contribution?"

An Elsevier transfer offer can be useful, but transfer is not acceptance. It is a routing suggestion. Before accepting, ask:

Accept transfer if the destination is truly aligned and you can repair the manuscript before evaluation. Decline if a different journal family is cleaner.

Maybe, but treat resubmission as a high bar. Consider it only if:

• the editor invited a revised submission or the rejection was narrow and repairable
• the pharmacotherapy bridge is now visible in the title, abstract, first figure, and cover letter
• the mechanism, dose-response logic, disease model, statistics, and validation now support the therapeutic claim
• the article type is correct
• review manuscripts include a review proposal that explains relevance, originality, timeliness, outline, key references, and author expertise
• competing interests, ethics, data availability, and author metadata are complete
• the cover letter explains why Biomedicine & Pharmacotherapy is the right audience rather than a disease-specific, delivery, oncology, natural-product, or mechanistic pharmacology journal

Do not resubmit if the editor clearly identified scope mismatch, if the paper belongs to a specialist reviewer pool, or if the missing evidence cannot be rebuilt.